Day: May 29, 2020

– Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response –– Data represent the first demonstration of PROTAC®-mediated degradation of a disease-causing protein in humans –NEW HAVEN, Conn., May 29, 2020 (GLOBE NEWSWIRE) —  Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced updated data from the dose escalation portion of the company’s Phase 1/2 clinical trial of ARV-110 in men with metastatic castration-resistant prostate cancer (mCRPC), to be shared as an oral presentation at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting on May 29, 2020. ARV-110 is a potent, selective, orally available androgen receptor (AR) degrader,...

NEW YORK, May 29, 2020 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that data from the GEMINI Phase 3 trial of AXS-05 in major depressive disorder (MDD) will be presented in oral and poster sessions at the 2020 Annual Meeting of the American Society for Clinical Psychopharmacology (ASCP), to be held virtually, May 29-30. AXS-05 (dextromethorphan/bupropion modulated delivery tablet) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.Below are the details of the presentations:Oral PresentationTitle: Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results from the GEMINI Phase 3, Double-Blind,...

MALVERN, Pa., May 29, 2020 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the company will be participating in the upcoming Jefferies Virtual Healthcare Conference.TELA Bio’s management is scheduled to present on Tuesday, June 2, 2020 at 9:00 AM Eastern Daylight Time (EDT). Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at ir.telabio.com.About TELA Bio, Inc.TELA Bio, Inc. is a commercial stage medical technology company focused on designing, developing, and marketing a new category of tissue...

BETHLEHEM, Pa., May 29, 2020 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, and microbiome laboratory and analytical services, today announced that it has entered into a definitive agreement to acquire privately owned UrSure, Inc. (“UrSure”) for cash.Based in Boston, UrSure is developing and commercializing products that measure adherence to HIV medications including pre-exposure prophylaxis or PrEP, the daily medication to prevent HIV. This includes laboratory-based tests that can measure levels of the medication in a patient’s urine or blood, as well as several additional point of care products in development. These products will allow healthcare professionals to assess patient adherence and determine with accuracy if the...

København, 29. maj 2020På den ordinære generalforsamling i EAC Invest A/S den 30. april 2020 blev det besluttet at annullere de egne aktier, som selskabet havde erhvervet i forbindelse med gennemførelsen af det omvendte aktiesplit, i alt nominelt kr. 802.570,825.Kapitalnedsættelsen er dags dato besluttet gennemført og endeligt registreret hos Erhvervsstyrelsen, se hertil selskabsmeddelelse nr. 20/2020 af 29. maj 2020.I forlængelse af ovenstående skal det med henvisning til § 32 i lovbekendtgørelse nr. 377 af 2. april 2020 om kapitalmarkeder oplyses, at, at selskabets samlede aktiekapital pr. dags dato udgør nominelt DKK 3.519.250 fordelt på aktier af DKK 350. Det samlede antal stemmer i selskabet udgør 10.055, inklusiv 104 resterende egne aktier. Med venlig hilsen,for EAC Invest A/SBestyrelsen For yderligere informationMartin Thaysen,...

Beregningen af indre værdier for samtlige afdelinger i Investeringsforeningen PFA Invest er forsinket som følge af tekniske udfordringer, og der anmodes derfor om suspension af samtlige afdelinger under Investeringsforeningen PFA Invest.Suspension gælder for følgende afdelinger:Eventuel henvendelse vedrørende denne meddelelse kan rettes til Stine Bernt Simonsen på sbs@pfa.dk eller på telefon 39 17 60 87.Med venlig hilsenPFA Asset Management A/S